CN1301125C - Medicine for treating gastrointestinal tract disease - Google Patents
Medicine for treating gastrointestinal tract disease Download PDFInfo
- Publication number
- CN1301125C CN1301125C CNB031590608A CN03159060A CN1301125C CN 1301125 C CN1301125 C CN 1301125C CN B031590608 A CNB031590608 A CN B031590608A CN 03159060 A CN03159060 A CN 03159060A CN 1301125 C CN1301125 C CN 1301125C
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- parts
- rhizoma
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a medicine for treating gastrointestinal tract diseases, which is prepared by mainly compounding the traditional Chinese medicines of lovely hemsleya roots, Chinese paris rhizome, medicinal evodia fruit, aucklandia roots, corydalis tuber, Rhizoma Bletillae, cuttlefish bone, largehead atractylodes rhizome, angelica, pilose asiabell roots, astragalus roots, liquorice, etc. Thus, the efficiency of all of the medicines generates synergistic effect to effectively treat gastrointestinal tract diseases. The medicine can be prepared into any common preparation for oral administration. The medicine has the functions of obvious alimentary tract canker resistance, strong spasmolysis and analgesia, obvious inflammation resistance, etc., has the certain efficiency of excrement promotion, has good therapeutic effect on alimentary tract canker, gastritis, enteritis, etc., and has the advantages of safety and no toxic or side effect.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of gastroenteropathy, relating in particular to a kind of is the medicine of primary raw material preparation with the Chinese herbal medicine.
Background technology
Gastroenteropathy such as gastric ulcer, duodenal ulcer, chronic colitis, chronic gastritis, gastrointestinal dysfunction are common clinically frequently-occurring diseases, wherein periodically abdomen pain of long-term, chronic repeatability appears in stomach, duodenal ulcer clinically, the course of disease reaches several months, several years, even the danger of cancerating is arranged; Anorexia, belch, vomiting, abdominal distention, diarrhoea, syndrome such as weak then appear in chronic gastritis, enteritis and gastrointestinal dysfunction, Western medicine just carries out part alleviation or treatment to gastroenteropathy, can't solve recurrence and safety non-toxic problem, facts have proved, this disease of treatment by Chinese herbs has the advantage that solves this difficult problem, but at present Chinese medicine preparation or curative effect on the market can not be satisfactory, or curative effect is pretty good but have certain toxic and side effects.
Summary of the invention
Therefore, still there is demand in people to the Chinese medicine preparation of the treatment gastroenteropathy of better efficacy and safety non-toxic, up to now, also do not find the report of any relevant medicine of the present invention.The inventor is through research repeatedly, and the checking repeatedly by long term toxicity test, acute toxicity test, animal and clinical trial, found the endo-medicine that the treatment of better curative effect and safety non-toxic gastroenteropathy is arranged finally, thereby finished the present invention.
The object of the present invention is to provide the medicine of the treatment gastroenteropathy of the better and safety non-toxic of a kind of warming spleen and stomach for dispelling cold, regulating QI to relieve pain, therapeutic effect.
Another object of the present invention is to provide the preparation method of this medicine.
The consumption of drug component of the present invention is also groped to sum up to draw through the inventor in a large number, and each amounts of components is for all to have better curative effect in the following weight parts scope:
Radix Hemsleyae Macrospermae 33-66 part Rhizoma Paridis 33-99 part Fructus Evodiae 30-50 part Radix Inulae 33-99 part
Rhizoma Corydalis 33-99 part Pseudobulbus Bletillae (Rhizoma Bletillae) 66-132 part Endoconcha Sepiae 66-132 part Rhizoma Atractylodis Macrocephalae 33-99 part
Radix Angelicae Sinensis 66-132 part Radix Codonopsis 33-99 part Radix Astragali 33-99 part Radix Glycyrrhizae 33-99 part
Be preferably:
66 parts of 33 parts of Radix Inulaes of 66 parts of Fructus Evodiaes of 50 parts of Rhizoma Paridis of Radix Hemsleyae Macrospermae
66 parts of 99 parts of Rhizoma Atractylodis Macrocephalaes of 99 portions of Endoconcha Sepiaes of 66 parts of Pseudobulbus Bletillae (Rhizoma Bletillae) of Rhizoma Corydalis
66 parts in 66 portions of Radix Glycyrrhizaes of 66 parts of Radixs Astragali of 99 parts of Radix Codonopsis of Radix Angelicae Sinensis
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations.But in order to make this medicine bring into play drug effect better, take all factors into consideration factors such as mouthfeel, cost, preferably this medicine is made water-honeyed pill.Wherein, all medical materials all do not extract, so all medical material compositions all can be obeyed down, but for medicine is absorbed easily, pulverizing medicinal materials are crossed sieve No. 6, owing to there being sufficient fineness to reach bigger specific surface area, so but the effective ingredient in the messenger drug be absorbed preferably; From disintegration with dose is less and cost consideration, comparatively desirable with refined honey and an amount of water pill; Adopt the active carbon coating to be because active carbon itself has the effect of convergence absorbing toxin and color and luster is stable is difficult for changing, help guaranteeing the quality of medicine.
Preferably, the preparation method of bolus of drug of the present invention:
With described materials of weight proportions medicine, be ground into fine powder, cross sieve No. 6, mixing, add the ratio of 20-30g refined honey in every 100g medicated powder, with refined honey and an amount of water pill, active carbon coating, 60 ℃ dry about 10 hours down, the Cera Chinensis polishing promptly gets the pill of this medicine.
Above-mentioned preparation method, wherein refined honey be Mel refine to water content be 15-18%.
Required various conventional adjuvant in the time of can adding preparation such as lubricant, binding agent different dosage form in the active component of medicine of the present invention, method of Chinese medicinal routinely is prepared into any peroral dosage form commonly used, as powder, tablet, capsule, oral liquid etc.
Medicine of the present invention has tangible anti-alimentary tract ulcer, stronger spasmolytic and analgesia, the tangible effect of effect such as antiinflammatory and certain tonneau stool, to very good and safe without toxic side effect of curative effect such as digestive tract ulcer, gastritis and enteritis.
The specific embodiment
Below further set forth the beneficial effect of medicine of the present invention by testing example, these test routine long term toxicity test, acute toxicity test, pharmacodynamics test and the clinical trial that has comprised bolus of drug of the present invention.
Test example 1: the long term toxicity test of bolus of drug of the present invention
(1) experiment purpose:, observe rat and irritate toxic reaction and the degree that this medicine of stomach is produced for a long time, to guarantee clinical application safety by the clinical preceding safety evaluatio requirement of new drug.
(2) material: tried thing and be bolus of drug of the present invention, specification: 4.5g/ wraps (every g is equivalent to crude drug 1.067g); Animal is 80 of SD rats, body weight 80-90g.
(3) method: animal is divided into 4 groups at random, 20 every group, male and female half and half, sub-cage rearing.Observe a week before the administration, wait situations such as each treated animal activity, feed, feces all no abnormal after, begin to like to try thing.
1. heavy dose of group: by 11.25g/kg/day (being equivalent to crude drug amount 12g/kg/day);
2. middle dosage group: by 5.63g/kg/day (being equivalent to crude drug amount 6g/kg/day);
3. small dose group: by 2.81g/kg/day (being equivalent to crude drug amount 3g/kg/day);
4. normal saline matched group: give NS by same capability.
Above-mentioned 4 groups all by 2ml/100g, every morning is irritated stomach once, amounts to for 12 weeks.Claim body weight weekly one time, and adjust dosage according to body weight; Timing takes by weighing feedstuff and calculates the feed consumption (g/kg/day) of each treated animal; Cage is looked on and is examined animal skin, eye, nose, mucosa, breathing, behavior, activity, feed, drinking-water and large and small just character etc.
After medication finishes, gather and check five hematological indices, 13 blood parameters; The animal of execution 1/2 carries out system's postmortem, and 1/2 animal is retained and observed for 2 weeks in addition.
(4) result: each dosage of bolus of drug of the present invention and NS matched group are all movable normal in 12 all experiment periods, and behavior is active.The hair color smoothness does not see that feces is unusual, none death; 4 treated animal body weight gain situations and feed consumption basically identical; Hematological examination 4 treated animal five indices are all in normal range, difference that relatively there are no significant between group; Blood biochemical detects each dosage group and compares with the NS matched group, and except that heavy dose group and small dose group T-CHO index, all the other all do not have significant difference; 13 kinds of internal organs outward appearances of 4 treated animals are normal, difference that there are no significant between 10 kinds of organ coefficient values.Pathological anatomy and histopathologic examination all do not have special pathological change.
(5) conclusion and discussion: in sum, show that this drug oral toxicology test does not have the overt toxicity reaction, does not see organ function and histology's abnormal change.
Test example 2: acute toxicity test
(1) experiment purpose: observe acute toxic reaction that mice produces and death condition behind the disposable filling stomach of medicine of the present invention.
(2) test drug: bolus of drug of the present invention, specification: 4.5g/ wraps (every g is equivalent to crude drug 1.067g).
(3) experimental animal: 20 of ICR mices, body weight are 18-22g, male and female half and half.
(4) method: the 1. preparation of medicine, get medicine 27g of the present invention, adding distil water 60ml; 2. the acute toxicity test of gastric infusion: with the medicinal liquid that is mixed with by maximum volume 0.4ml/10g in disposable filling stomach at 9 o'clock in the morning, observed 7 days continuously after the administration, the record animal poisons and death condition.
(5) result of the test: do not see that any toxic reaction appears in animal, all animals survival, activity freely, feed drinking-water and defecation are all normal, the body weight normal growth, ordinary circumstance is good.
(6) conclusion: in sum, the maximum tolerated dose of this medicine of mouse stomach is greater than 18g/kg (being equivalent to crude drug amount 19.2g/kg), more than 80 times of clinical recommended dose 225mg/kg (crude drug amount 240mg/kg) have been reached, also do not see the overt toxicity reaction, the acute toxicity of the disposable administration of prompting this product is very little.
Test example 3: the pharmacodynamics test of medicine of the present invention
(1) purpose: test adopts multiple acute and chronic gastric ulcer model to estimate the protective effect of this medicine to gastric mucosa injury and ulcer emphatically, studies the influence of spasmolytic, antiinflammatory, analgesia and small intestinal peristalsis effect simultaneously, thereby provides the pharmacodynamics foundation for clinical practice.
(2) material: 1. animal: ICR mice and SD rat, male and female are all used; Cavia porcellus, male and female are regardless of.2. medicine and reagent: bolus of drug of the present invention, specification: 4.5g/ wraps (every g is equivalent to crude drug 1.067g); Aspirin, lot number 980818 is provided by Kunming pharmaceutical factory; Stomach-recovering capsule, the 0.4g/ grain, lot number 001202 is produced (ZZ-3675 defends the accurate word ZF-126 of medicine number) by Shijiazhuang Ke Di pharmaceutical Co. Ltd; SIDASHU JIAONANG, the 200mg/ grain, lot number 010715 is commercially available, and Xiuzheng Pharmaceutical Group. Jilin limited company produces; Dimethylbenzene is available from Wuhan organic synthesis factory, specification 500ml, analytical pure.3. instrument: U-135C self-balancing recorder, day island proper Tianjin company product.
(3) method
The rat medication: 20 times by clinical recommended dose 0.225g/kg prepare medicines, promptly take by weighing this medicine 4.5g and add normal saline 20ml, rat is irritated stomach with the 2ml/100g body weight and promptly obtains high dose 4.5g/kg (clinical consumption 20 times), dosage 2.25g/kg in half-and-half obtaining after the dilution successively again (clinical consumption 10 times) and low dosage 1.125g/kg (clinical consumption 5 times); Aspirin 0.2g is dissolved in the sodium carbonate liquor of 20ml1%; Stomach-recovering capsule 1.6g is dissolved in the 20ml normal saline; SIDASHU JIAONANG 200mg adds normal saline to 20ml.
The mice medication: 20 times by clinical recommended dose 0.225g/kg prepare medicines, promptly take by weighing this medicine 4.5g and add normal saline 20ml, rat is irritated stomach with the 2ml/100g body weight and promptly obtains high dose 4.5g/kg (clinical consumption 20 times), dosage 2.25g/kg in half-and-half obtaining after the dilution successively again (clinical consumption 10 times) and low dosage 1.125g/kg (clinical consumption 5 times); Aspirin 0.2g is dissolved in the sodium carbonate liquor of 20ml1%.
Above-mentioned medicine is all now with the current, is provided with down test and uses.
Medicine of the present invention has been done following test: to the influence of isolated guinea pig ileum smooth muscle contraction; The contrast stomach-recovering capsule has been done the influence that the influence to rat water logging stress gastric ulcer, influence that hydrochloric acid-ethanol causes rat pipe film injury and acetic acid cause rat gastric ulcer; The contrast SIDASHU JIAONANG has been done the influence that hydrochloric acid-ethanol causes rat gastric ulcer; The contrast aspirin has been made analgesia and the antiinflammatory action to mice; Influence to the mouse small intestine motion.
(4) discussion and conclusion: 1. Chinese People's Anti-Japanese Military and Political College Mus water logging stress ulcer effect: can cause behind the water logging animal that gastric acid, pepsin and gastrin increase, and cause stress ulcer.This result of the test shows that medicine of the present invention has dosage correlation and obviously resists the rat stress ulcer effect.2. to the protective effect of hydrochloric acid-ethanol-type ulcer: hydrochloric acid-ethanol-type ulcer is the peptic ulcer characteristics of simulation hyperchlorhydria and drinks to the stimulation of gastric mucosa and the acute ulcer model of chemical inflammation; result of the test shows; medicine of the present invention has antiacid effect, and the gastrointestinal mucosa damage that chemical substances such as ethanol are caused simultaneously has protective effect.3. promote the healing effect of rat acetic acid type chronic ulcer: the gastric ulcer that acetic acid causes is a kind of incidence rate height, favorable reproducibility and easy experimental technique, the anthropoid chronic peptic ulcer of class, this result of the test shows that this medicine 2.25 and 4.5g/kg promptly have the effect of remarkable promotion ulcer healing.4. suppress the contraction of ileum smooth muscle: the result shows that medicine of the present invention is concentration dependent and obviously suppresses the inductive smooth muscle shrinks function of acetylcholine and histamine.Prompting this product can be alleviated the gastrointestinal smooth muscle of spasticity, thereby has the effect of control gastrointestinal convulsion.5. reduce acetic acid and cause the mouse writhing number of times: show that medicine of the present invention has stronger spasmolytic and analgesic activity, because this product has stronger spasmolytic and analgesic activity, so this product can be alleviated the stomachache that gastrointestinal convulsion and ulcer cause.6. medicine of the present invention has tangible antiinflammatory action: gastrointestinal ulceration is followed acute and chronic inflammation in various degree mostly, because this medicine also has tangible antiinflammatory action, helps the control of gastrointestinal ulceration equally.7. medicine of the present invention is to the influence of enterokinesia: the medicine of the present invention of high dose is irritated the progradation that can obviously promote mouse small intestine behind the stomach, and prompting this product has the effect of certain tonneau stool.
In sum, medicine of the present invention has the better protect effect to gastrointestinal ulceration, and the intestinal tube smooth muscle is had tangible spasmolysis, shows stronger analgesia and antiinflammatory action simultaneously.This research is used to prevent and treat stomach, duodenal ulcer, chronic gastritis, enteritis, colitis etc. for it is clinical provide theory and experimental basis.
Test example 4: the clinical observation of Drug therapy gastroenteropathy of the present invention
(1) test case standard
Tcm diagnosis standard: have following clinical manifestation: gastral cavilty distending pain, anorexia, abdominal distention after meal, big loose stool are thin, limbs asthenia, hematemesis, black stool, lusterless complexion, acid regurgitation, red tongue, yellow fur, floating and thready pulse.
Western medicine diagnose standard: relate to diseases such as doctor trained in Western medicine stomach, duodenal ulcer, acute or chronic gastritis (shallow, erosive, atrophic), acute chronic enteritis, gastrointestinal dysfunction and all carry out by the up-to-date diagnostic criteria of this disease.
Exclusion standard: merge liver, kidney, the heart, disease of hematopoietic system, psychotic and do not meet the standard of including in, not taking medicine in accordance with regulations affects the treatment observes etc.
(2) test medication: bolus of drug of the present invention, specification: 4.5g/ wraps (every g is equivalent to crude drug 1.067g)
Usage: per day for adults three times, each bag; Child every day three times, each 1/3-1/2 bag.
The course of treatment: gastric ulcer patient January-one course of treatment of March; Chronic gastritis, chronic enteritis patient January-one course of treatment of February; One course of treatment of acute gastritis, acute enteritis patient's first quarter moon.
(3) health giving quality observation
Cardinal symptom: upper abdominal pain number of times, degree; Stool have or not black stool, shapeless, have loose bowels; Abdominal distention; Acid regurgitation.
Minor symptom: belch, feel sick, loss of appetite, body be tired.
Safety observation: select some cases to carry out blood, urine, just routine test regulating liver-QI kidney function test.
(4) clinical efficacy criterion
Clinical recovery: cardinal symptom and minor symptom are all eliminated, ulcer focus or gastritis foci disappearance.
Produce effects: cardinal symptom, minor symptom are obviously improved, and ulcer focus or gastritis focus disappear substantially.
Effectively: cardinal symptom and minor symptom all have improvement, and focus dwindles 40%.
Invalid: cardinal symptom, minor symptom do not have improvement, and focus is less than 30%.
(5) result and analysis
Ordinary circumstance is analyzed: treatment gastroduodenal ulcer 67 examples, wherein male 45 examples, women 22 examples; 170 examples such as treatment gastroduodenitis, gastrointestinal dysfunction, wherein male 107 examples, women 63 examples; Treat 237 examples altogether, wherein male 152 examples, women 85 examples, gastroenteritic ulcer group and gastroenteritis group sex difference do not have significance.Gastroenteritic ulcer group minimal ages 24 years old, maximum 63 years old age, 40.2 years old mean age, gastroenteritis group minimal ages 8 years old, at maximum 70 years old age, 38.4 years old mean age, two groups of age differencess do not have significance.The shortest course of disease of gastroenteritic ulcer group 1 year, the longest course of disease 25 years, average course of disease 8 years, the shortest course of disease of gastroenteritis group January, the longest course of disease 34 years, average course of disease 7.9 years, two groups of course of disease differences do not have significance.The gastric ulcer group is followed up a case by regular visits to 57 examples, follow-up rate 85.1%, and the gastroenteritis group is followed up a case by regular visits to 138 examples, and 81.2%, two group of follow-up rate difference of follow-up rate does not have significance.Groups such as stomach duodenal ulcer group and gastroenteritis in sex, age, the course of disease, the aspect such as to follow up a case by regular visits to be suitable.
Clinical curative effect analysis such as gastroduodenal ulcer and gastroenteritis: gastroenteritic ulcer group treatment gastroduodenal ulcer 67 examples, cure rate 53.7%, obvious effective rate 40%, effective percentage 4.8%, total effective rate 98.5%; 170 examples such as treatment gastrointestinal dysfunction, enteritis, cure rate 55.3%, obvious effective rate 32.3%, effective percentage 11.8%, total effective rate 994%, two groups of total effective rates are that 99.2%, two group of clinical therapeutic efficacy difference does not have significance, can think that curative effects such as Drug therapy gastroduodenal ulcer of the present invention, acute chronic enteritis, acute or chronic gastritis and gastrointestinal dysfunction are better.(seeing the following form)
| Group | Cure | Produce effects | Effectively | Invalid | Add up to | Total effective rate (%) | The P value |
| Gastroenteritic ulcer group gastroenteritis group | 44 94 | 19 55 | 3 20 | 1 1 | 67 170 | 98.50 99.40 | Uc＝0.5532 P＝0.5801 |
| Add up to | 138 | 74 | 23 | 2 | 237 | 99.20 | - |
The various symptoms and therapeutic effect of treatment gastroenteropathy: the various symptom curative effects of treatment gastroenteropathy are better, total effective rate is more than 94%, gastroenteritic ulcer group gastroenteritis group is except big informal letter, abdomen ache, abdominal distention difference has the significance the equal zero difference of other each index (seeing the following form)
| Group | Cure | Produce effects | Effectively | Invalid | Add up to | Total effective rate (%) | The P value |
| Stool gastroenteritic ulcer group gastroenteritis group stomachache gastroenteritic ulcer group gastroenteritis group abdominal distension gastroenteritic ulcer group gastroenteritis group sour regurgitation gastroenteritic ulcer group gastroenteritis group belch gastroenteritic ulcer group gastroenteritis group appetite gastroenteritic ulcer group gastroenteritis group spirit gastroenteritic ulcer group gastroenteritis group limbs gastroenteritic ulcer group | 56 126 62 136 62 134 64 121 63 135 61 147 60 140 55 | 1 15 0 6 1 5 0 0 0 0 1 0 1 0 1 | 1 17 3 24 0 19 1 5 1 7 1 8 0 4 1 | 2 3 0 2 1 9 1 5 2 4 2 8 1 6 3 | 63 161 65 168 64 167 66 131 66 146 65 163 62 150 60 | 96.8 98.1 100.0 98.8 98.4 94.6 98.5 96.2 97.0 97.3 97.0 95.1 98.4 96.0 95.0 | Uc＝24929 P＝0.0172 Uc＝2.7302 P＝0.0063 Uc＝3.1429 P＝0.0017 Uc＝1.2680 P＝0.2048 Uc＝0.7781 P＝0.4365 Uc＝0.8954 P＝0.3706 Uc＝0.9988 P＝0.3179 Uc＝0.4446 |
| The gastroenteritis group | 142 | 0 | 5 | 5 | 152 | 96.7 | P＝0.6566 |
The gastroenteritic ulcer group is followed up a case by regular visits to 57 examples, the stable curative effect time is the shortest 1 year, the longest 15 years, average 8.0 years, the gastroenteritis group was followed up a case by regular visits to 138 examples, the stable curative effect time is the shortest 2 years, the longest 13 years, average 5.1 years, two groups are followed up a case by regular visits to stable curative effect average time was 5.8 years, following up a case by regular visits to stable curative effect comparing difference average time for two groups does not have significance, and the result shows that the Drug therapy gastrointestinal disease stable curative effect time of the present invention is longer.
To two groups carry out hematuria routine examination and liver, the kidney check result is all no abnormal, proves that medicine of the present invention is without any side effects, to hemopoietic system, liver, renal function nonhazardous.
In sum, safety of medicine of the present invention has no side effect, and being one is worth recommending treatment stomach, duodenal ulcer, acute and chronic gastritis, an effective and safe medicine of acute and chronic enteritis.
Come further to set forth the preparation method of bolus of drug of the present invention by the following examples.
Embodiment 1:
Take by weighing raw material by following amount:
Radix Hemsleyae Macrospermae 50g, Rhizoma Paridis 66g, Fructus Evodiae 33g, Radix Inulae 66g, Rhizoma Corydalis 66g, Pseudobulbus Bletillae (Rhizoma Bletillae) 99g, Endoconcha Sepiae 99g, Rhizoma Atractylodis Macrocephalae 66g, Radix Angelicae Sinensis 99g, Radix Codonopsis 66g, Radix Astragali 66g, Radix Glycyrrhizae 66g, standby.
With the above-mentioned raw materials medicine, be ground into fine powder, cross sieve No. 6, mixing is 15% refined honey 263g and an amount of water pill with water content, cross sieve 28g coating No. eight with needle-use activated carbon, drying is 10 hours under 60 ℃, with Cera Chinensis 1.1g polishing, promptly gets the pill of this medicine, the heavy 0.52g of per 10 balls, every bag 0.45g.
Embodiment 2:
Take by weighing raw material by following amount:
Radix Hemsleyae Macrospermae 33g, Rhizoma Paridis 33g, Fructus Evodiae 30g, Radix Inulae 33g, Rhizoma Corydalis 33g, Pseudobulbus Bletillae (Rhizoma Bletillae) 66g, Endoconcha Sepiae 66g, Rhizoma Atractylodis Macrocephalae 33g, Radix Angelicae Sinensis 66g, Radix Codonopsis 33g, Radix Astragali 33g, Radix Glycyrrhizae 33g, standby.
With the above-mentioned raw materials medicine, be ground into fine powder, cross sieve No. 6, mixing is 15% refined honey 100g and an amount of water pill with water content, sent out sieve 28g coating with pin No. eight with activity, drying is 10 hours under 60 ℃, with Cera Chinensis 1.1g polishing, promptly gets the pill of this medicine, the heavy 0.52g of per 10 balls, every bag 0.45g.
Embodiment 3:
Take by weighing raw material by following amount:
Radix Hemsleyae Macrospermae 66g, Rhizoma Paridis 99g, Fructus Evodiae 50g, Radix Inulae 99g, Rhizoma Corydalis 99g, Pseudobulbus Bletillae (Rhizoma Bletillae) 132g, Endoconcha Sepiae 132g, Rhizoma Atractylodis Macrocephalae 99g, Radix Angelicae Sinensis 132g, Radix Codonopsis 99g, Radix Astragali 99g, Radix Glycyrrhizae 99g, standby.
With the above-mentioned raw materials medicine, be ground into fine powder, cross sieve No. 6, mixing is 15% refined honey 263g and an amount of water pill with water content, cross sieve 28g coating No. eight with needle-use activated carbon, drying is 10 hours under 60 ℃, with Cera Chinensis 1.1g polishing, promptly gets the pill of this medicine, the heavy 0.52g of per 10 balls, every bag 0.45g.
Claims (3)
1, a kind of medicine for the treatment of gastroenteropathy is characterized in that it is the medicament of being made by following raw medicaments in portion by weight:
Radix Hemsleyae Macrospermae 33-66 part Rhizoma Paridis 33-99 part Fructus Evodiae 30-50 part Radix Inulae 33-99 part
Rhizoma Corydalis 33-99 part Pseudobulbus Bletillae (Rhizoma Bletillae) 66-132 part Endoconcha Sepiae 66-132 part Rhizoma Atractylodis Macrocephalae 33-99 part
Radix Angelicae Sinensis 66-132 part Radix Codonopsis 33-99 part Radix Astragali 33-99 part Radix Glycyrrhizae 33-99 part.
2, the medicine of treatment gastroenteropathy as claimed in claim 1 is characterized in that the consumption of each crude drug is:
66 parts of 33 parts of Radix Inulaes of 66 parts of Fructus Evodiaes of 50 parts of Rhizoma Paridis of Radix Hemsleyae Macrospermae
66 parts of 99 parts of Rhizoma Atractylodis Macrocephalaes of 99 portions of Endoconcha Sepiaes of 66 parts of Pseudobulbus Bletillae (Rhizoma Bletillae) of Rhizoma Corydalis
66 parts in 66 portions of Radix Glycyrrhizaes of 66 parts of Radixs Astragali of 99 parts of Radix Codonopsis of Radix Angelicae Sinensis.
3, the preparation method of medicine as claimed in claim 1 or 2 is characterized in that:
With described materials of weight proportions medicine, be ground into fine powder, cross sieve No. 6, mixing adds the ratio of 20-30g refined honey in every 100g medicated powder, with refined honey and an amount of water pill, active carbon coating, 60 ℃ dry 10 hours down, the Cera Chinensis polishing promptly gets pill.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031590608A CN1301125C (en) | 2003-09-12 | 2003-09-12 | Medicine for treating gastrointestinal tract disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031590608A CN1301125C (en) | 2003-09-12 | 2003-09-12 | Medicine for treating gastrointestinal tract disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1493356A CN1493356A (en) | 2004-05-05 |
| CN1301125C true CN1301125C (en) | 2007-02-21 |
Family
ID=34240924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031590608A Expired - Fee Related CN1301125C (en) | 2003-09-12 | 2003-09-12 | Medicine for treating gastrointestinal tract disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301125C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985878B (en) * | 2005-12-20 | 2011-06-22 | 广州王老吉药业股份有限公司 | Medicine composition for treating peptic ulcer and its preparing method |
| CN102784206B (en) * | 2012-08-30 | 2014-08-20 | 青岛大学医学院附属医院 | Niweikang and preparation method thereof |
| CN115969933B (en) * | 2022-06-20 | 2024-05-03 | 红云制药(昆明)有限公司 | Polishing method for hemsleya amabilis stomach and intestine pills |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061910A (en) * | 1991-11-27 | 1992-06-17 | 姚昌礼 | Process for preparing diabetes medicine-ketangping |
| CN1273845A (en) * | 1999-05-13 | 2000-11-22 | 马斌 | Gastritis capsule |
-
2003
- 2003-09-12 CN CNB031590608A patent/CN1301125C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1061910A (en) * | 1991-11-27 | 1992-06-17 | 姚昌礼 | Process for preparing diabetes medicine-ketangping |
| CN1273845A (en) * | 1999-05-13 | 2000-11-22 | 马斌 | Gastritis capsule |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1493356A (en) | 2004-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1683001A (en) | Chinese medicine for treating gout | |
| CN105663546B (en) | Traditional Chinese medicine composition for treating proventriculitis of chicken | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN1686501A (en) | Compound Chinese medicine for treating child diarrhea and its preparation method | |
| CN1301125C (en) | Medicine for treating gastrointestinal tract disease | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| CN1931302A (en) | Chinese medicine composition for treating urethral calculus and gallstones and its prepn process | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN1284588C (en) | Medicine for treating gastrointestinal tract diseases | |
| CN1197614C (en) | Chinese medicine cap sule for treating prostatic disorders | |
| CN1857605A (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN100389796C (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1264540C (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1242791C (en) | Medicinal mixture and its preparation method | |
| CN103156961B (en) | Medicine composition used for treating common cold, wind cold, and lung and stomach heat stagnation | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| CN107260851B (en) | Traditional Chinese medicine composition for treating deficiency constipation | |
| CN1814131A (en) | Chinese medicine for treating astriction and preparing method | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN102920968A (en) | Application of traditional Chinese medicine composition to preparation of helicobacter pylori resisting medicine | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1308031C (en) | Chinese medicine composition for treating biliary tract disease, preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070221 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |